Latest Content

New data reveals Caplyta significantly improves remission rates in adults with major depressive disorder, offering hope for lasting relief from symptoms.

Centanafadine demonstrates promising effects on ADHD symptoms, enhancing key neurotransmitters without increasing psychomotor activity, according to poster data.

Axsome Therapeutics begins a pivotal trial for AXS-14, aiming to improve fibromyalgia management and address significant patient needs.

Innovative combinations of transcranial magnetic stimulation and ketamine therapy offer new hope for treatment-resistant depression, pain, and substance use disorders.

A clinician shares her journey as a 3-time suicide survivor, advocating for vulnerability and compassion in mental health care.

New data reveals valbenazine (Ingrezza) shows significantly higher VMAT2 target occupancy than deutetrabenazine (Austedo XR).

Psychiatrists explore the mental health impacts of protests, emphasizing the need for community support and ethical responsibility in turbulent times.

Explore groundbreaking insights from the 2025 Southern Florida Psychiatry Conference, covering VNS for depression, stuttering management, and postpartum care.

Explore the transformative impact of artificial intelligence on modern life, from health care advancements to productivity enhancements and ethical considerations.

A look at upcoming presentations at APSARD 2026, January 15-18.

FDA removes suicidal ideation warnings from GLP-1 RA medications, highlighting their potential benefits in weight loss and mental health treatment.

"I’m idling on the parking garage roof..."

Exploring the complex legacy of Oliver Sacks, this article examines the blurred lines between truth and fiction in his case studies.